Elvitegravir - Gilead Sciences

Drug Profile

Elvitegravir - Gilead Sciences

Alternative Names: GS-9137; JTK-303; Vitekta

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Japan Tobacco
  • Developer Gilead Sciences; Japan Tobacco
  • Class Antiretrovirals; Quinolones; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 27 Oct 2017 Gilead Sciences completes a phase II/III trial in HIV-1 infections (Combination therapy, Treatment experienced, In adolescents, In children, In infants) in Italy, Germany, Spain, Thailand, South Africa, USA and Uganda (PO, tablets) (NCT01923311)
  • 23 Aug 2017 No recent reports on development identified - Phase-III for HIV-1 infections (Combination therapy, Treatment-experienced) in Japan (PO)
  • 27 Feb 2017 Gilead Sciences has patent protection for Elvitegravir in USA and European Union (Gilead Sciences 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top